Amit Pant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Amit Pant has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Rupesh Vitthalrao Chikhale
Department of Pharmaceutical and Biological Chemistry, School of Pharmacy, University College London, London WC1N 1AX, UK
7 shared publications Pramod Khedekar
Department of Pharmaceutical Sciences, CADD Lab, Mahatma Jyotiba Fuley Shaikshanik Parisar, Rashtrasant Tukadoji Maharaj Nagpur University, Amravati Road, Nagpur, 440 033 MS, India
3 shared publications- Daniel Hassan
Discipline of Pharmaceutical Sciences, College of Health Sciences, University of KwaZulu-Natal, Private Bag X54001, Durban, South Africa
2 shared publications - Joshua Chukwufumnanya Nwabuife
Discipline of Pharmaceutical Sciences, College of Health Sciences, University of KwaZulu-Natal , Durban , South Africa
2 shared publications - Mohammed Ali Gafar
Discipline of Pharmaceutical Sciences, College of Health Sciences, University of KwaZulu-Natal, Private Bag X54001 Durban, South Africa; Department of Pharmaceutics, Faculty of Pharmacy, University of Khartoum, Khartoum P.O. Box 1996, Sudan
2 shared publications Nawras Osman
2 shared publications
Latest Publications
- Open Access
- 25 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10386
Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) in Inflammation and Disease: Mechanisms, Therapeutic Potential, and Future Directions
Triggering receptor expressed on myeloid cells-1 (TREM-1), a member of the immunoglobulin superfamily, plays a crucial role in amplifying inflammatory responses, thereby contributing to the pathogenesis and progression of various inflammatory diseases. This review presents a comprehensive analysis of the current understanding of TREM-1 signaling and its dysregulation in disease pathology. Additionally, it explores the prognostic significance of TREM-1 across a spectrum of conditions. Targeting TREM-1 signaling represents a promising therapeutic approach for managing a wide range of diseases, including cancer, neurodegenerative disorders, cardiovascular diseases, and other inflammation-driven conditions. Previous reviews on TREM-1 have largely focused on its immunological role across diverse disease conditions and selective peptide-based inhibitors targeting its signaling pathway. However, recent discoveries have identified small-molecule modulators of TREM-1 that offer new opportunities for therapeutic intervention. Incorporating these findings would provide a more comprehensive and updated perspective on TREM-1 biology, particularly regarding its molecular regulation, drug-target potential, and translational relevance in inflammatory and immune-mediated disorders. Advances in this field are expected to be driven by structure-based drug design, particularly in the development of TREM-1 inhibitors. However, further research is needed to elucidate the predictive value of TREM-1 alterations and to evaluate them in prospective human studies prior to clinical decision-making.
- 25 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10386
Open AccessTriggering Receptor Expressed on Myeloid Cells-1 (TREM-1) in Inflammation and Disease: Mechanisms, Therapeutic Potential, and Future Directions
Triggering receptor expressed on myeloid cells-1 (TREM-1), a member of the immunoglobulin superfamily, plays a crucial role in amplifying inflammatory responses, thereby contributing to the pathogenesis and progression of various inflammatory diseases. This review presents a comprehensive analysis of the current understanding of TREM-1 signaling and its dysregulation in disease pathology. Additionally, it explores the prognostic significance of TREM-1 across a spectrum of conditions. Targeting TREM-1 signaling represents a promising therapeutic approach for managing a wide range of diseases, including cancer, neurodegenerative disorders, cardiovascular diseases, and other inflammation-driven conditions. Previous reviews on TREM-1 have largely focused on its immunological role across diverse disease conditions and selective peptide-based inhibitors targeting its signaling pathway. However, recent discoveries have identified small-molecule modulators of TREM-1 that offer new opportunities for therapeutic intervention. Incorporating these findings would provide a more comprehensive and updated perspective on TREM-1 biology, particularly regarding its molecular regulation, drug-target potential, and translational relevance in inflammatory and immune-mediated disorders. Advances in this field are expected to be driven by structure-based drug design, particularly in the development of TREM-1 inhibitors. However, further research is needed to elucidate the predictive value of TREM-1 alterations and to evaluate them in prospective human studies prior to clinical decision-making.
- 12 July 2023
- Published by Elsevier in Bioorganic Chemistry
- Vol. 139, 106720
Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy
- 12 July 2023
- Published by Elsevier in Bioorganic Chemistry
- Vol. 139, 106720
Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy
- Open Access
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Novel Vancomycin Free Base – Sterosomes for Combating Diseases Caused by Staphylococcus Aureus Infections (S. Aureus and MRSA)
A clarion call to save antibiotics and other antimicrobials is the need for the evolution of novel drug delivery systems to combat resistance posed by Staphylococcus aureus and Methicillin- resistant Staphylococcus aureus (S. aureus and MRSA) to the conventional drug delivery systems. Herein, we present a novel vancomycin free base – sterosomes (VCM-FB – Sterosomes) for vancomycin free base (VCM-FB) delivery against S. aureus and MRSA. VCM-FB – Sterosomes were prepared by employing the thin-film hydration method and assessed in terms of their physicochemical, in silico, in vitro and in vivo properties. A preliminary biocompatibility evaluation on MCF-7 and HEK-293 cell lines was also carried out on the VCM-FB – Sterosomes formulation using in vitro cytotoxicity assay. The cytotoxicity results revealed the viability of cell to be above 70% for all the cell lines after exposure to VCM-FB – Sterosomes, therefore indicating its biosafety. VCM-FB – Sterosomes had hydrodynamic diameter (DH), polydispersity index (PDI) and a surface-charge (ζ) of 114.14 ± 0.59 nm, 0.210 ± 0.02 and +36.3 ± 5.42 mV respectively, with an entrapment efficiency (EE%), drug loading capacity (DLC%) and VCM-FB release after 48-hour of 79.61 ± 0.59%, 90.91% w/w and 54.95 ± 9.75% respectively. In silico studies showed VCM-FB – Sterosomes to self-assemble in five nano seconds and was stable thereafter. Stability studies also showed the VCM-FB – Sterosomes formulation to be stable over a period of 90 days while the in vitro haemolytic studies showed VCM-FB – Sterosomes to be non-hemolytic. Interestingly, the VCM-FB – Sterosomes showed 2-fold superior minimum inhibition efficiency (MIC) against S. aureus and MRSA relative to bare VCM-FB with MICs of 1.95 µg/mL and 0.98 µg/mL for VCM-FB and VCM-FB – Sterosomes (S. aureus), and 7.81 µg/mL and 3.91 µg/mL for VCM-FB and VCM-FB – Sterosomes (MRSA), respectively. Blank Sterosomes were also observed to be effective against these bacteria, with greater effectiveness observed against MRSA. Faster bacterial killing time was also recorded for VCM-FB – Sterosomes compared to bare VCM-FB.Greater damage to the MRSA membrane was indicated by an increase and decrease in electrical conductivity, and protein/DNA concentration, respectively. VCM-FB – Sterosomes were observed to exhibit a superior reduction of matured MRSA biofilm (27.22%) compared to VCM-FB (2.53%). In vivo BALB/c mice-infected skin model showed VCM-FB – Sterosomes to have a more significant MRSA eradication of 27-fold compared to bare VCM-FB, which showed an approximately 4-fold MRSA eradication. The result of this study amplifies the superior efficiency of VCM-FB – Sterosomes for the treatment of S. aureus and MRSA infections compared to conventional form of VCM-FB.
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Open AccessNovel Vancomycin Free Base – Sterosomes for Combating Diseases Caused by Staphylococcus Aureus Infections (S. Aureus and MRSA)
A clarion call to save antibiotics and other antimicrobials is the need for the evolution of novel drug delivery systems to combat resistance posed by Staphylococcus aureus and Methicillin- resistant Staphylococcus aureus (S. aureus and MRSA) to the conventional drug delivery systems. Herein, we present a novel vancomycin free base – sterosomes (VCM-FB – Sterosomes) for vancomycin free base (VCM-FB) delivery against S. aureus and MRSA. VCM-FB – Sterosomes were prepared by employing the thin-film hydration method and assessed in terms of their physicochemical, in silico, in vitro and in vivo properties. A preliminary biocompatibility evaluation on MCF-7 and HEK-293 cell lines was also carried out on the VCM-FB – Sterosomes formulation using in vitro cytotoxicity assay. The cytotoxicity results revealed the viability of cell to be above 70% for all the cell lines after exposure to VCM-FB – Sterosomes, therefore indicating its biosafety. VCM-FB – Sterosomes had hydrodynamic diameter (DH), polydispersity index (PDI) and a surface-charge (ζ) of 114.14 ± 0.59 nm, 0.210 ± 0.02 and +36.3 ± 5.42 mV respectively, with an entrapment efficiency (EE%), drug loading capacity (DLC%) and VCM-FB release after 48-hour of 79.61 ± 0.59%, 90.91% w/w and 54.95 ± 9.75% respectively. In silico studies showed VCM-FB – Sterosomes to self-assemble in five nano seconds and was stable thereafter. Stability studies also showed the VCM-FB – Sterosomes formulation to be stable over a period of 90 days while the in vitro haemolytic studies showed VCM-FB – Sterosomes to be non-hemolytic. Interestingly, the VCM-FB – Sterosomes showed 2-fold superior minimum inhibition efficiency (MIC) against S. aureus and MRSA relative to bare VCM-FB with MICs of 1.95 µg/mL and 0.98 µg/mL for VCM-FB and VCM-FB – Sterosomes (S. aureus), and 7.81 µg/mL and 3.91 µg/mL for VCM-FB and VCM-FB – Sterosomes (MRSA), respectively. Blank Sterosomes were also observed to be effective against these bacteria, with greater effectiveness observed against MRSA. Faster bacterial killing time was also recorded for VCM-FB – Sterosomes compared to bare VCM-FB.Greater damage to the MRSA membrane was indicated by an increase and decrease in electrical conductivity, and protein/DNA concentration, respectively. VCM-FB – Sterosomes were observed to exhibit a superior reduction of matured MRSA biofilm (27.22%) compared to VCM-FB (2.53%). In vivo BALB/c mice-infected skin model showed VCM-FB – Sterosomes to have a more significant MRSA eradication of 27-fold compared to bare VCM-FB, which showed an approximately 4-fold MRSA eradication. The result of this study amplifies the superior efficiency of VCM-FB – Sterosomes for the treatment of S. aureus and MRSA infections compared to conventional form of VCM-FB.
- Open Access
- 1 July 2017
- Published by Scientific Scholar in Arabian Journal of Chemistry
- Vol. 10 (5) , 715-725
Facile and efficient synthesis of benzoxazole derivatives using novel catalytic activity of PEG-SO 3 H
A highly efficient, simple and rapid method for the preparation of various 2-aminobenzoxazoles and other benzoxazole derivatives using a catalytic amount of poly (ethylene glycol)-bound sulfonic acid (PEG-SO3H) is described. PEG-SO3H is found to be an economical and reusable catalyst with low catalytic loading. The percent yield was found to be satisfactory, experimental set up and purification of final products are facile and easy
- 1 July 2017
- Published by Scientific Scholar in Arabian Journal of Chemistry
- Vol. 10 (5) , 715-725
Open AccessFacile and efficient synthesis of benzoxazole derivatives using novel catalytic activity of PEG-SO 3 H
A highly efficient, simple and rapid method for the preparation of various 2-aminobenzoxazoles and other benzoxazole derivatives using a catalytic amount of poly (ethylene glycol)-bound sulfonic acid (PEG-SO3H) is described. PEG-SO3H is found to be an economical and reusable catalyst with low catalytic loading. The percent yield was found to be satisfactory, experimental set up and purification of final products are facile and easy
- 6 June 2017
- Published by Elsevier in Letters in Drug Design & Discovery
- Vol. 14 (6)
Molecular Docking, Synthesis and CNS Activity of Some Novel 1, 4-Benzodiazepine Derivatives
Background: A series of new class of twenty four 1, 4-benzodizepines were designed and by using molecular docking study with GABAA receptor, high scoring fourteen molecules were synthesized from this library. Binding affinity of ligands towards GABAA was evaluated on the basis of dock score and bonding interactions like hydrogen bonds, hydrophobic bonds and pi-stacking. Methods: All compounds were found to possess a good dock score, but varied in the formation of bonding interactions. Methoxy group substituted ligands showed particularly very important role in these interactions. All the synthesized molecules were characterized by IR, 1H-NMR and Mass spectrometric data and investigated for their antianxiety and antiepileptic actions. Conclusion: Compound 3-(3-ethoxy-4-hydroxybenzylidene)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin- 2-one was found to possess very effective in both the activities. All results, docking as well as pharmacological evaluations were compared to diazepam.
- 6 June 2017
- Published by Elsevier in Letters in Drug Design & Discovery
- Vol. 14 (6)
Molecular Docking, Synthesis and CNS Activity of Some Novel 1, 4-Benzodiazepine Derivatives
Background: A series of new class of twenty four 1, 4-benzodizepines were designed and by using molecular docking study with GABAA receptor, high scoring fourteen molecules were synthesized from this library. Binding affinity of ligands towards GABAA was evaluated on the basis of dock score and bonding interactions like hydrogen bonds, hydrophobic bonds and pi-stacking. Methods: All compounds were found to possess a good dock score, but varied in the formation of bonding interactions. Methoxy group substituted ligands showed particularly very important role in these interactions. All the synthesized molecules were characterized by IR, 1H-NMR and Mass spectrometric data and investigated for their antianxiety and antiepileptic actions. Conclusion: Compound 3-(3-ethoxy-4-hydroxybenzylidene)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin- 2-one was found to possess very effective in both the activities. All results, docking as well as pharmacological evaluations were compared to diazepam.
- 1 October 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 23 (20) , 6689-6713
Design, synthesis and pharmacological evaluation of pyrimidobenzothiazole-3-carboxylate derivatives as selective L-type calcium channel blockers
- 1 October 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 23 (20) , 6689-6713
Design, synthesis and pharmacological evaluation of pyrimidobenzothiazole-3-carboxylate derivatives as selective L-type calcium channel blockers
- Open Access
- 27 May 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (S3) , P18
LEDGF/p75 IN interaction inhibitors: in silico studies of an old target with novel approach
- 27 May 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (S3) , P18
Open AccessLEDGF/p75 IN interaction inhibitors: in silico studies of an old target with novel approach
- Open Access
- 27 May 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (S3) , E24
Development of dual inhibitors targeting DprE1 and AHAS for treatment of Mycobacterium tuberculosis infection
- 27 May 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (S3) , E24
Open AccessDevelopment of dual inhibitors targeting DprE1 and AHAS for treatment of Mycobacterium tuberculosis infection
- Open Access
- 1 January 2012
- Published by ScopeMed in Materia Socio Medica
- Vol. 24 (4) , 268-273
Smallest Organism; Highest Threat
Ever since the discovery of virus in beginning of 20th century, infections caused by these organisms have captured attention of researchers. The evolution of viruses is still a controversy, even same for their categorization in either living or non-living. It is clear that besides many controversies virus remains challenging to treat as well as to control in some extent. Though vaccines are available as prophylactic tool and antiviral drugs for treatment, still virus exist in host cells if they successfully invade biological machinery. Now it remains as challenge to treat these smallest organisms with high degree of efficacy and safety. To answer the demand of the present world there is urgent need of more potent and novel drugs for treatment and vaccines to prevent infection. Answer to this problem will definitely reduce casualties occurring worldwide. This review presents few of the pandemics, their causative agents, current status of treatment and future prospective.
- 1 January 2012
- Published by ScopeMed in Materia Socio Medica
- Vol. 24 (4) , 268-273
Open AccessSmallest Organism; Highest Threat
Ever since the discovery of virus in beginning of 20th century, infections caused by these organisms have captured attention of researchers. The evolution of viruses is still a controversy, even same for their categorization in either living or non-living. It is clear that besides many controversies virus remains challenging to treat as well as to control in some extent. Though vaccines are available as prophylactic tool and antiviral drugs for treatment, still virus exist in host cells if they successfully invade biological machinery. Now it remains as challenge to treat these smallest organisms with high degree of efficacy and safety. To answer the demand of the present world there is urgent need of more potent and novel drugs for treatment and vaccines to prevent infection. Answer to this problem will definitely reduce casualties occurring worldwide. This review presents few of the pandemics, their causative agents, current status of treatment and future prospective.